Shares of Myovant were up nearly 30% on Monday on record trading volume after Wall Street learned that its parent company Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and women’s health. The deal is worth up to $4.2 billion in upfront and potential milestone payments. Both … Continue reading “Myovant Explodes on Pfizer Prostate Cancer Drug Collaboration News”
